



SpecialtyRx.GiantEagle.com  
1-844-259-1891

## Patient Information

New Patient     Current Patient

### Patient's Name

First \_\_\_\_\_ Last \_\_\_\_\_ MI \_\_\_\_\_

Male     Female

Last 4 digits of SSN \_\_\_\_\_ Date of Birth \_\_\_\_\_

Street Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_

Preferred Phone \_\_\_\_\_  Landline     Mobile

Alternate Phone \_\_\_\_\_  Landline     Mobile

Preferred Method of Contact     Call     Text

Email Address \_\_\_\_\_

Patient's Primary Language     English     Other    If other, please specify \_\_\_\_\_

### Parent/Guardian Name (if under 18)

Home Phone \_\_\_\_\_ Cell Phone \_\_\_\_\_

Email Address \_\_\_\_\_

### Alternate Caregiver/Contact

OK to speak to/leave message with alternate caregiver/contact

Home Phone \_\_\_\_\_ Cell Phone \_\_\_\_\_

Email Address \_\_\_\_\_

**PLEASE ATTACH COPY OF FRONT AND BACK OF PATIENT'S INSURANCE CARD**



## Prescriber Information

Date Prescription Needed \_\_\_\_\_

Ship to Office     Patient Pickup at Retail     Ship to Home

Office Hours to Receive Shipment of Medication \_\_\_\_\_

Office Contact and Title \_\_\_\_\_

Office Contact Phone \_\_\_\_\_

**Patient's Name**

First \_\_\_\_\_ Last \_\_\_\_\_ MI \_\_\_\_\_

Date of Birth \_\_\_\_\_

Primary ICD-10 code \_\_\_\_\_ Has the patient been on this therapy before?  Yes  No

Patient weight \_\_\_\_\_ kg Date recorded \_\_\_\_\_

TB Test Results and Date \_\_\_\_\_

Has Hepatitis B been ruled out?  Yes  No Date \_\_\_\_\_

If No, has treatment been initiated?  Yes  No

New therapy induction  Therapy change

**Other therapies tried and failed:**

Other biologics \_\_\_\_\_ Date \_\_\_\_\_

Methotrexate Date \_\_\_\_\_

Oral medications \_\_\_\_\_ Date \_\_\_\_\_

Topical medications \_\_\_\_\_ Date \_\_\_\_\_

PUVA

UVB

Other \_\_\_\_\_ Date \_\_\_\_\_

Additional justification for drug \_\_\_\_\_

Does the patient have a latex allergy?  Yes  No

NKDA  Known drug allergies \_\_\_\_\_

Is the patient on concurrent methotrexate?  Yes  No

Concurrent Medications \_\_\_\_\_

**Prescribing Information**

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Cibinqo (abrocitinin)	<input type="checkbox"/> 50mg tablet <input type="checkbox"/> 100mg tablet <input type="checkbox"/> 200mg tablet	<input type="checkbox"/> Take 50mg by mouth once daily <input type="checkbox"/> Take 100mg by mouth once daily <input type="checkbox"/> Take 200mg by mouth once daily	Qty: <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____

## Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Cimzia (certolizumab pegol)	<input type="checkbox"/> 200mg/mL prefilled syringe starter kit (1 kit = 6 syringes; 3 doses)	<b>Starter:</b> Inject 400mg subcutaneously at weeks 0, 2, and 4	Qty: 1 kit Refills: 0
	<input type="checkbox"/> 200mg/mL prefilled syringe	<b>Maintenance:</b> <input type="checkbox"/> Inject 200mg subcutaneously every other week <input type="checkbox"/> Inject 400mg subcutaneously every other week <input type="checkbox"/> Inject 400mg subcutaneously every 4 weeks	Qty: <input type="checkbox"/> 2 prefilled syringes <input type="checkbox"/> 4 prefilled syringes <input type="checkbox"/> 6 prefilled syringes Refills: _____
<input type="checkbox"/> Cosentyx (secukinumab)  <b>ADULT</b>	<input type="checkbox"/> 150mg/mL prefilled syringe <input type="checkbox"/> 150mg/mL Sensoready auto-injector <input type="checkbox"/> 300mg/2mL UnoReady Pen	<b>Starter:</b> <input type="checkbox"/> Inject 150mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 150mg every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 300mg every 4 weeks	Qty: <input type="checkbox"/> 5 devices <input type="checkbox"/> 10 devices Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 150mg subcutaneously once every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously once every 4 weeks	Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 2 devices <input type="checkbox"/> 3 devices <input type="checkbox"/> 6 devices Refills: _____
<input type="checkbox"/> Cosentyx (secukinumab)  <b>PEDIATRIC</b> Patient weight _____kg	<input type="checkbox"/> 75mg/0.5mL prefilled syringe <input type="checkbox"/> 150mg/mL Sensoready auto-injector <input type="checkbox"/> 150mg/mL prefilled syringe	<b>Starter:</b> <input type="checkbox"/> Inject 75mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 75mg once every 4 weeks <input type="checkbox"/> Inject 150mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 150mg once every 4 weeks	Qty: 5 devices Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 75mg subcutaneously once every 4 weeks <input type="checkbox"/> Inject 150mg subcutaneously once every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously once every 4 weeks	Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 2 devices <input type="checkbox"/> 3 devices <input type="checkbox"/> 6 devices Refills: _____
<input type="checkbox"/> Dupixent (dupilumab)  <b>ADULT</b>	<input type="checkbox"/> 300mg/2mL prefilled syringe <input type="checkbox"/> 300mg/2mL pen-injector	<b>Starter:</b> <input type="checkbox"/> Inject 600mg subcutaneously once	Qty: 2 devices Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 300mg subcutaneously every other week	Qty: <input type="checkbox"/> 2 device <input type="checkbox"/> 6 devices Refills: _____

# Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Dupixent (dupilumab) <b>PEDIATRIC</b> Patient weight _____ kg	<input type="checkbox"/> 200mg/1.14mL prefilled syringe <input type="checkbox"/> 200mg/1.14mL pen-injector ( <b>≥12 years</b> ) <input type="checkbox"/> 300mg/2mL prefilled syringe <input type="checkbox"/> 300mg/2mL pen-injector ( <b>≥12 years</b> )	<b>Starter:</b> <input type="checkbox"/> Inject 400mg subcutaneously once <input type="checkbox"/> Inject 600mg subcutaneously once	Qty: 2 devices Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 200mg subcutaneously every other week <input type="checkbox"/> Inject 300mg subcutaneously every other week <input type="checkbox"/> Inject 200mg subcutaneously every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously every 4 weeks	<input type="checkbox"/> Qty: <input type="checkbox"/> 2 devices <input type="checkbox"/> 4 devices Other (must be multiples of 2): _____ Refills: _____
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 25mg/0.5mL vial <input type="checkbox"/> 25mg/0.5mL prefilled syringe <input type="checkbox"/> 50mg/mL prefilled syringe <input type="checkbox"/> 50mg/mL Sureclick auto-injector <input type="checkbox"/> 50mg/mL Mini Cartridge	<b>Starter:</b> <input type="checkbox"/> Inject 50mg subcutaneously twice weekly for 3 months	Qty: <input type="checkbox"/> 8 devices <input type="checkbox"/> 24 devices Refills: _____
		<b>Maintenance:</b> <input type="checkbox"/> Inject 50mg subcutaneously once weekly <input type="checkbox"/> Other: _____	Qty: <input type="checkbox"/> 4 devices <input type="checkbox"/> 12 devices Other: _____ Refills: _____
<input type="checkbox"/> Ilumya (tildrakizumab-asmn)	100mg/mL prefilled syringe	<b>Starter:</b> <input type="checkbox"/> Inject 100mg subcutaneously at weeks 0, 4, and every 12 weeks thereafter	Qty: 2 syringes Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 100mg subcutaneously every 12 weeks	Qty: 1 syringe Refills: _____
<input type="checkbox"/> Humira (adalimumab)	<b>Starter:</b> <input type="checkbox"/> <b>CITRATE FREE Psoriasis/Uveitis or adolescent HS Starter Kit</b> (1 x 80mg/0.8mL and 2x 40mg/0.4mL) pen-injector  <input type="checkbox"/> <b>HS Starter Kit</b> (3x 80mg/0.8mL) pen-injector	<input type="checkbox"/> <b>Psoriasis/Uveitis/adolescent HS Starter:</b> Inject 80mg subcutaneously on day 1 as a single dose, then inject 40mg subcutaneously every other week beginning 1 week after the initial dose on day 8  <input type="checkbox"/> <b>HS Starter:</b> Inject 160mg subcutaneously on day 1 followed by 80mg subcutaneously 2 weeks later on day 15	Qty: 1 kit Refills: 0
	<b>Maintenance:</b> <b>CITRATE FREE</b> <input type="checkbox"/> 40mg/0.4mL pen-injector <input type="checkbox"/> 40mg/0.4mL prefilled syringe <input type="checkbox"/> 80mg/0.8mL pen-injector <b>ORIGINAL FORMULATION</b> <input type="checkbox"/> 40mg/0.8mL pen-injector <input type="checkbox"/> 40mg/0.8mL prefilled syringe	<b>Maintenance:</b> <input type="checkbox"/> Inject 40mg subcutaneously every other week <input type="checkbox"/> Inject 40mg subcutaneously every week <input type="checkbox"/> Inject 80mg subcutaneously every other week	Qty: <input type="checkbox"/> 2 devices <input type="checkbox"/> 4 devices <input type="checkbox"/> 6 devices <input type="checkbox"/> Other (must be in multiples of 2): _____ Refills: _____

## Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Olumiant (baricitinib)	<input type="checkbox"/> 2mg tablet <input type="checkbox"/> 4mg tablet	<input type="checkbox"/> Take 2mg by mouth once daily <input type="checkbox"/> Take 4mg by mouth once daily	Qty: <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____
<input type="checkbox"/> Opzelura (ruxolitinib)	60 gram tube	Apply a thin layer topically to affected area twice daily	Qty: <input type="checkbox"/> 1 tube <input type="checkbox"/> 2 tubes <input type="checkbox"/> 3 tubes Refills: _____
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 125mg/mL ClickJect auto-injector <input type="checkbox"/> 125mg/mL prefilled syringe	Inject 125mg subcutaneously once weekly	Qty: <input type="checkbox"/> 4 devices <input type="checkbox"/> 12 devices Refills: _____
<input type="checkbox"/> Otezla (apremilast)  CrCL: _____	<input type="checkbox"/> 55 tablet Starter pack (consisting of 10mg-20mg-30mg tablets for 28 days)	<b>Starter:</b> Take by mouth as directed per package	Qty: 1 starter pack Refills: 0
	<input type="checkbox"/> 30mg tablet	<b>Maintenance:</b> <input type="checkbox"/> Take 1 tablet by mouth twice daily <input type="checkbox"/> Other: _____	Qty: <input type="checkbox"/> 60 tablets <input type="checkbox"/> 180 tablets <input type="checkbox"/> Other: _____ Refills: _____
<input type="checkbox"/> Remicade (infliximab) OR biosimilar  <input type="checkbox"/> Avsola (infliximab-axxq) <input type="checkbox"/> Inflectra (infliximab-dyyb) <input type="checkbox"/> Renflexis (infliximab-abda)	100mg vial	<b>Starter:</b> Infuse _____mg (5mg/kg) intravenously at week 0, 2, and 6, then every 8 weeks thereafter  Patient weight: _____ kg  <b>Maintenance:</b> Infuse _____mg (5mg/kg) intravenously every 8 weeks  Patient weight: _____ kg	Qty: _____ vial(s) Refills: _____
<input type="checkbox"/> Rinvoq (upadacitinib)	<input type="checkbox"/> 15mg tablet <input type="checkbox"/> 30mg tablet	<input type="checkbox"/> Take 15mg by mouth once daily <input type="checkbox"/> Take 30mg by mouth once daily	Qty: <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____
<input type="checkbox"/> Siliq (brodalumab)	210mg/1.5mL prefilled syringes (2 pack)	<b>Starter:</b> <input type="checkbox"/> Inject 210mg subcutaneously at weeks 0,1, and 2 followed by 210mg every 2 weeks	Qty: 4 syringes Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 210mg subcutaneously every 2 weeks	Qty: <input type="checkbox"/> 2 syringes <input type="checkbox"/> 6 syringes Refills: _____

## Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 50mg/0.5mL Smartject auto-injector <input type="checkbox"/> 50mg/0.5mL prefilled syringe	Inject 50mg subcutaneously once per month	Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 3 devices Refills: _____
<input type="checkbox"/> Simponi Aria (golimumab)  <b>ADULT</b> Patient weight: _____ kg	50mg/4mL vial	<b>Starter:</b> <input type="checkbox"/> Administer _____ mg (2mg/kg) intravenously at weeks 0, 4, then every 8 weeks thereafter	Qty: _____ vial(s) Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Administer _____ mg (2mg/kg) intravenously every 8 weeks	Qty: _____ vial(s) Refills: _____
<input type="checkbox"/> Simponi Aria (golimumab)  <b>PEDIATRIC</b> Patient weight: _____ kg	50mg/4mL vial	<b>Starter:</b> <input type="checkbox"/> Administer _____ mg (80mg/m <sup>2</sup> ) intravenously at weeks 0, 4, then every 8 weeks thereafter	Qty: _____ vial(s) Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Administer _____ mg (80mg/m <sup>2</sup> ) intravenously every 8 weeks	Qty: _____ vial(s) Refills: _____
<input type="checkbox"/> Sotyktu (deucravacitinib)	6 mg tablet	Take 6mg by mouth once daily	Qty: <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____
<input type="checkbox"/> Skyrizi (risankizumab-rzaa)	<input type="checkbox"/> 150mg/mL prefilled syringe <input type="checkbox"/> 150mg/mL auto-injector	<b>Starter:</b> <input type="checkbox"/> Inject 150mg subcutaneously at weeks 0,4, and then every 12 weeks thereafter	Qty: 2 devices Refills: 0
		<b>Maintenance:</b> <input type="checkbox"/> Inject 150mg subcutaneously every 12 weeks	Qty: 1 device Refills: _____

# Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> <b>Stelara</b> (ustekinumab) _____ Patient weight: _____ kg	<input type="checkbox"/> 45mg/0.5mL prefilled syringe <input type="checkbox"/> 90mg/mL prefilled syringe	<p><b>Starter:</b></p> <input type="checkbox"/> Inject 45mg subcutaneously at weeks 0,4, and then every 12 weeks thereafter <input type="checkbox"/> Inject 90mg subcutaneously at weeks 0,4, and then every 12 weeks thereafter	Qty: 2 prefilled syringes Refills: 0
<input type="checkbox"/> <b>Taltz</b> (ixekizumab)	<input type="checkbox"/> 80mg/mL autoinjector <input type="checkbox"/> 80mg/mL prefilled syringe	<p><b>Plaque psoriasis (Ps) Starter:</b></p> <input type="checkbox"/> Inject 160mg (2 injections) subcutaneously once at week 0, followed by 80mg at weeks 2,4,6,8,10, and 12, then 80mg every 4 weeks	<input type="checkbox"/> 8 devices (Ps) <input type="checkbox"/> 2 devices (PsA) Refills 0
<input type="checkbox"/> <b>Tremfya</b> (guselkumab)	<input type="checkbox"/> 100mg/mL auto-injector <input type="checkbox"/> 100mg/mL prefilled syringe	<p><b>Starter:</b></p> <input type="checkbox"/> Inject 100mg subcutaneously at weeks 0,4, and every 8 weeks thereafter	Qty: 2 devices Refills: 0
<input type="checkbox"/> Other: _____		<p><b>Maintenance:</b></p> <input type="checkbox"/> Inject 100mg subcutaneously every 8 weeks	Qty: 1 device Refills: _____
			Qty: _____ Refills: _____

Prescriber Name \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email Address \_\_\_\_\_

Office Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_

State License \_\_\_\_\_ DEA \_\_\_\_\_ NPI \_\_\_\_\_

In order for brand name to be dispensed, prescriber must hand write "Brand Medically Necessary" or "Brand Necessary" in the space below:

\_\_\_\_\_

I authorize this prescription and for Giant Eagle Specialty Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process.

Prescriber signature required. NO STAMPS. Prescriber attests this is his/her legal signature.

Prescriber signature \_\_\_\_\_ Date \_\_\_\_\_